Dyslipidemia is a key independent risk factor for coronary heart disease(CAD),which in turn promotes the growth of Atherosclerosis and related cardiovascular events. Dyslipidemia has been strongly linked to the pathophysiology of cardiovascular diseases(CVDs).

About 25-30% of urban and 15-20% of rural individuals in india have dyslipidemia,2019.

Statins,cholesterol absorption inhibitors,fibrates,nicotinic acid,and others are frequently used drugs in the pharmacologocal intervention in dyslipidemia,but their use is associated with serious side effects like myalgias,arthralgias,dyspepsia,hepatic toxicity,and others.

Dyslipidemia can be understood in Ayurveda in terms of Medoroga,a disorder caused by medo dhatu vriddhi, which can lead to bahutwa and abaddhatwa of medo datu.

Given the prevalence and adverse effects of long tern use of contemporary interventions,it is necessary for more effective, and cost efficient medicines to control the illness and serve society.

Though numerous Ayurvedic formulations have been demonstrated to have anti-hyperlipidemic efficacy with no documented side effects, there is still scope for more research in this field.

Thus yogarajaguggulu,a medohara yoga,mentioned by Acharya sharangdhara, attributed with Hypolipidemic,Cardio protective and Hepatoprotective activity is taken for the present study.

Navakaguggulu consisting of maricha,pippali,shunti,harithaki,vibhitaki,amalaki,chitraka, and musta mentioned by bhaishajyaratnavali, being a proven drug for medoroga is taken as control drug.

E78.9 is the ICD-10-CM code used for diagnosing Disorder for lipoprotein metabolism,unspecified.

EF-3 is the specific code as per NAMASTE PORTAL (National Ayush Morbidity and standardized terminologies electrical portal) for Medoroga.